Compare Halliburton Company (HAL) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Hinge Health Inc. Class A Common Stock — how do they compare? Halliburton Company trades at $32.91 (market cap $27.32B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Halliburton Company is far larger — about 3.2× Hinge Health Inc. Class A Common Stock's market cap, and Halliburton Company pays a 2.07% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| HAL | HNGE | |
|---|---|---|
Market Cap | $27.32B | $8.48B |
Volume | 5,347,556 | 879,799 |
Sector | Energy | Health |
52-Week High | $42.98 | $105.14 |
52-Week Low | $21.82 | $31.17 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $33.47B | $8.10B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.83, up 0.71% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a P/E of 17.17 and ROE of 14.89%, though 2025 net income declined to $1.28B from $2.5B in 2024. Recent developments include Venezuela energy agreements and a Cyprus deepwater contract win, positioning for international growth amid volatile oil markets.
Wall Street maintains strong bullish sentiment with 73% buy ratings and a $43.11 price target, representing 31% upside. Key risks include oil price volatility and execution challenges in new markets. The stock offers value with reasonable valuation metrics but faces near-term headwinds from declining profitability trends.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
